Endogenous CD4(+) T cells recognize neoantigens in lung cancer patients, including recurrent oncogenic KRAS and ERBB2 (Her2) driver mutations

T cells specific for neoantigens encoded by mutated genes in cancers are increasingly recognized as mediators of tumor destruction after immune checkpoint inhibitor therapy or adoptive cell transfer. Much of the focus has been on identifying epitopes presented to CD8(+) T cells by class I MHC. Howev...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Res
Autors principals: Veatch, Joshua R., Jesernig, Brenda L., Kargl, Julia, Fitzgibbon, Matthew, Lee, Sylvia M., Baik, Christina, Martins, Renato, Houghton, A. McGarry, Riddell, Stanley R.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6584616/
https://ncbi.nlm.nih.gov/pubmed/31043415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0402
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars